The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
The firm said that it planned to lay off its oncology sales team in order to focus on women's health, despite launching an oncology business unit last spring.
In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.
The firm's CEO Ramji Srinivasan said the layoffs would help focus the company on developing relationships with clinicians and medical providers.
In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.
The company said it earned approximately $128 million in revenue in 2015, and accessioned 42,000 total commercial diagnostic test samples.
Dragged down by sinking sales and test volumes at IDL, GeneNews looks to restructure its business.
The company plans to lay off 145 employees at its Mountain View headquarters, as well as 15 in San Jose, 13 in Sunnyvale, and six in San Francisco.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.